Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3).
The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $137M
Founded date: 2012
Investors 11
Show more
Funding Rounds 5
| Date | Series | Amount | Investors |
| 27.04.2023 | Series E | $53M | Lumira Ven... |
| 05.11.2021 | Series D | $31M | - |
| 11.07.2018 | Series C | $15M | - |
| 30.03.2017 | Series C | $22M | Brace Phar... |
| 06.08.2015 | Series B | $16M | - |
Mentions in press and media 18
| Date | Title | Description |
| 27.04.2023 | Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO | Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV Infections |
| 27.04.2023 | Antiva Biosciences Closes $53M Series E Equity Financing | Anitva Logo Antiva Biosciences, a South San Francisco, CA-based biopharmaceutical company developing topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, raised $53M in Series E fu... |
| 27.04.2023 | Antiva Biosciences Closes $53 Million Series E Equity Financing and Names Kristine Ball President and CEO | - |
| 05.11.2021 | Antiva Biosciences Closes $31 Million Series D Equity Financing | Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $31 million Series D equity ... |
| 02.11.2021 | Antiva Biosciences Closes $31 Million Series D Equity Financing | - |
| 02.11.2021 | Antiva Biosciences Closes $31 Million Series D Equity Financing | SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, tod... |
| 16.08.2018 | A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it | SOUTH SAN FRANCISCO, Calif. — The startup’s pitch seems compelling, even commonsensical: About 500,000 women in the U.S. need surgery every year for precancerous cervical lesions caused by the human papillomavirus. The surgery can lead to d... |
| 11.07.2018 | Antiva Biosciences Closes $15M Series C-1 Financing | Antiva Biosciences, a South San Francisco, CA-based biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, raised $15m in Series C-1 finan... |
| 10.07.2018 | Antiva Biosciences Closes $15 Million Series C-1 Financing | SOUTH SAN FRANCISCO, California, /PRNewswire/ — Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $1... |
| 30.03.2017 | Antiva Biosciences Closes $22M Series | SOUTH SAN FRANCISCO, CA, Biopharmaceutical company has raised a $22 million Series C. >> Click here for more funding data on Antiva Biosciences >> To export Antiva Biosciences funding data to PDF and Excel, click here Ant... |
Show more